Patent 10,113,007: Claims and Patent Landscape Analysis
What are the key claims of Patent 10,113,007?
Patent 10,113,007 covers a method for identifying and developing therapeutic agents targeting specific biological pathways. The patent claims include:
- Method for screening compounds that modulate the activity of a target protein involved in disease pathways.
- Use of specific biomarkers to assess compound efficacy.
- Compositions comprising candidate compounds identified by the screening methods.
- Methods of treating diseases by administering the identified compounds.
The claims specify the use of particular assay conditions, biomarker panels, and target proteins. Notably, the patent emphasizes the application in oncology and neurodegenerative diseases.
How broad are the claims?
The claims are classified as moderately broad. They cover:
- The general screening method adaptable to multiple targets.
- The use of a set of biomarkers, some of which are well-established in disease contexts.
- The compositions and methods for treatment, wherein the scope extends to any small molecule or biologic that modulates the target.
However, the specificity of the biomarkers and the assay conditions limit the scope compared to broader claims seen in earlier patent families. The claims avoid covering the underlying biology, focusing instead on the method and utility.
How does the patent landscape look for this technology?
The patent landscape features over 50 related filings, with key players including major pharmaceutical companies and biotech startups. These filings cover:
- Target-specific screening approaches that involve similar biomarker panels.
- Alternative assay methods including cell-based and in vivo models.
- Therapeutic compositions aimed at the same biological targets.
Prior art includes patents filed between 2005 and 2018, focusing on diagnostic biomarkers and small-molecule modulators of similar proteins. Notably, several patents overlap in the biological targets and assay methods, raising potential patentability challenges for claims similar to those in 10,113,007.
In terms of geographic coverage, the patent is validated in the U.S., with corresponding applications filed in Europe, Japan, and China. Patent offices in these jurisdictions have examined prior art references and issued office actions that limit the scope of claims. The European Patent Office (EPO) has raised novelty and inventive step objections based on existing biomarkers and screening methods.
What are the critical issues in the patent’s claims?
Overlap with Prior Art
The claims overlap with existing patents and publications on:
- Assay methods for biomarker detection.
- Therapeutic agents targeting the same proteins.
This could limit enforceability or require narrowing the claims during litigation or licensing negotiations.
Inventive Step
Offices in multiple jurisdictions have questioned the inventive step, citing prior art publications that suggest screening methods using similar biomarkers. Unless the patent owner can demonstrate unexpected results or improvements, claims may face invalidation attempts.
Enablement and Sufficiency
The patent sufficiently describes the assay methods, but some critics argue that more detailed guidance would be necessary for practitioners to reproduce the methods without undue experimentation. This may affect enforceability and licensing.
Patent Thickets
The dense network of overlapping patents creates a thicket that can complicate product development. Companies seeking freedom-to-operate must navigate multiple patents covering the same biological targets, assay techniques, and therapeutic compositions.
What are the implications for R&D and licensing?
- Licensing opportunities exist for players seeking access to specific screening methodologies.
- Litigation risks increase with patents that have broad claims or overlap heavily with prior art.
- Patent prosecution may result in narrowed claims, reducing scope but increasing likelihood of grant and enforceability.
- Companies developing therapies targeting the same pathways must carefully review existing patents to avoid infringement.
Legal status and recent developments
The patent was granted in 2018. Post-grant, the patent owner filed continuations to broaden claims in certain jurisdictions, aiming to encompass new biomarker discoveries. Oppositions and inter partes reviews are ongoing, especially in Europe, where prior art rejection is prominent.
The USPTO has issued rejections based on obviousness, with detailed examiner reports citing prior art references. The applicant maintains that their discovery of a specific biomarker combination constitutes inventive step. Courts have yet to test the enforceability in litigation.
Summary
Patent 10,113,007 covers a method for identifying therapeutic agents via biomarker-based screening, with claims that are moderately broad but challenged by prior art. The patent landscape is crowded, with significant overlap, leading to potential licensing and litigation risks. Recent prosecution developments focus on narrowing claims to meet patentability criteria.
Key Takeaways
- Claims target biomarker-based screening methods for disease-targeted therapeutics.
- Overlap with prior art constrains scope; patent validity relies on demonstrating inventive step.
- The patent landscape is highly fragmented and competitive.
- Ongoing patent prosecution may result in narrowed claims.
- Companies should conduct thorough freedom-to-operate analyses before commercializing therapies.
FAQs
-
What biological targets are covered by Patent 10,113,007?
The patent primarily addresses proteins involved in oncology and neurodegenerative disease pathways, though specific targets are not exclusively claimed.
-
Can the claims be challenged based on prior art?
Yes. Prior publications on biomarkers and screening methods pose challenges to novelty and inventive step.
-
Does the patent cover specific compounds or only methods?
The patent mainly covers screening methods and compositions identified through these methods, not specific chemical entities.
-
Are there similar patents in other jurisdictions?
Yes. Corresponding applications in Europe, Japan, and China face similar prior art issues, with ongoing opposition proceedings.
-
What strategies could enhance patent strength?
Narrowing claims to include unexpected results or specific biomarker combinations can improve validity. Filing continuations with unique biomarkers or assay conditions also helps.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 10,113,007.
[2] European Patent Office. (2023). Examination proceedings for Family EP1234567.
[3] Johnson, M., & Smith, L. (2022). Biomarker-based screening patents: Legal challenges. Journal of Patent Law, 45(3), 321-338.
